We are live on ! Find out more

Ocugen

OCGN

Market cap $359M

1.06 USD

-0.27

20.3%

At close Updated Sep 9, 4:00 PM EDT

Pre-market

After hours

1.16

+0.10

9.43%

1 day

-20.3%

5 days

-20.9%

1 month

-19.08%

3 months

-14.52%

6 months

-36.14%

Year to date

-23.19%

1 year

2.91%

5 years

-85.6%

10 years

-99.51%

About: Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").

Employees: 116

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 6.7%

Neutral 86.7%

Negative 6.7%

Zacks Investment Research

OCGN Advances Gene Therapy OCU410 In Phase III for Geographic Atrophy

Ocugen moves OCU410 into phase III for geographic atrophy, with FDA-aligned study plans. The company expects to file a BLA for OCU410 in 2028.

OCGN Advances Gene Therapy OCU410 In Phase III for Geographic Atrophy

Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

MALVERN, Pa., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the first patient was dosed in the global Phase 3 registrational trial of OCU410 (AAV5-hRORA), its first-in-class modifier gene therapy candidate for GA secondary to dry age-related macular degeneration (dAMD). The Company also highlighted the recent FDA RMAT designation for OCU410, which supports a potential accelerated development and review pathway for the program.

Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Ocugen to Participate in Upcoming September Investor and Industry Conferences

MALVERN, Pa., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform at upcoming investor and industry conferences in September 2026.

Ocugen to Participate in Upcoming September Investor and Industry Conferences

Ocugen Targets 2027 BLA Filings as Gene Therapy Programs Near Key Readouts

Ocugen NASDAQ: OCGN is positioning its ophthalmology gene therapy portfolio around treatments for inherited retinal diseases and dry age-related macular degeneration, with pivotal-stage programs in retinitis pigmentosa, Stargardt disease and geographic atrophy, Chairman, CEO and Co-Founder Shankar Musunuri said during a Canaccord discussion.

Ocugen Targets 2027 BLA Filings as Gene Therapy Programs Near Key Readouts

Zacks Investment Research

Ocugen's Q2 Earnings Miss Estimates as R&D Costs Rise, Stock Falls

OCGN posts a wider Q2 loss as R&D spending climbs, while advancing late-stage gene therapy programs and extending its cash runway into 2028.

Ocugen's Q2 Earnings Miss Estimates as R&D Costs Rise, Stock Falls

Ocugen Q2 Earnings Call Highlights

Ocugen NASDAQ: OCGN said its second quarter marked progress across its late-stage ophthalmology pipeline, including FDA clearance to begin a Phase III study of OCU410 in geographic atrophy and an RMAT designation for the program.

Ocugen Q2 Earnings Call Highlights

Ocugen, Inc. (OCGN) Q2 2026 Earnings Call Transcript

Ocugen, Inc. (OCGN) Q2 2026 Earnings Call Transcript

Ocugen, Inc. (OCGN) Q2 2026 Earnings Call Transcript

Zacks Investment Research

Ocugen (OCGN) Reports Q2 Loss, Beats Revenue Estimates

Ocugen (OCGN) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to a loss of $0.05 per share a year ago.

Ocugen (OCGN) Reports Q2 Loss, Beats Revenue Estimates

Ocugen Provides Business Update with Second Quarter 2026 Financial Results

Conference Call and Webcast Today at 8:30 a.m. ET Received U.S. Food and Drug Administration (FDA) clearance to initiate OCU410 Phase 3 trial for geographic atrophy (GA), secondary to dry age-related macular degeneration (AMD); on track to initiate Phase 3 this quarter Granted Regenerative Medicine Advanced Therapy (RMAT) designation by FDA for OCU410, enabling eligibility for priority review and accelerated approval Signed a binding term sheet with Roots Pharmaceutical, and its strategic partner Al-Dhow International Holding, to negotiate an exclusive license for OCU400 in retinitis pigmentosa (RP) across the Middle East and North Africa (MENA) region Successfully completed OCU400 Process Performance Qualification (PPQ) batches, supporting Biologics License Application (BLA) and commercial launch supplies Closed $130.0 million convertible senior notes financing, extending cash runway into 2028 Remain on track to announce top-line results for two late-stage clinical programs, OCU400 for RP and OCU410ST for Stargardt disease in 1Q 2027 and 2Q 2027, respectively Strengthened leadership team with the appointments of Mohamed Genead, M.D.

Ocugen Provides Business Update with Second Quarter 2026 Financial Results

Ocugen to Participate in Upcoming August Investor Conferences

MALVERN, Pa., July 31, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform at upcoming investor conferences in August 2026.

Ocugen to Participate in Upcoming August Investor Conferences

See News Rankings

Price charts implemented using Lightweight Charts™